Wilson Disease

In suspected Wilson disease with acute liver failure, obtain copper-directed testing promptly but do not delay transfer to a liver-transplant center while awaiting ceruloplasmin, 24-hour urinary copper, or hepatic copper results; these markers may be difficult to obtain or interpret in fulminant disease. Liver transplantation is typically necessary in fulminant hepatic failure and is generally reserved for acute liver failure or decompensated cirrhosis. Wiley+2WileyIs it possible to diagnose fulminant Wilson's disease with ...Wolters KluwerWilson Disease | ContinuumPubMedClinical Review - Trientine Hydrochloride (MAR-Trientine) - NCBI Bookshelf

For decompensated cirrhosis without acute liver failure, involve transplant hepatology while initiating disease-specific therapy. AASLD- and ESPGHAN-aligned guidance has proposed initial chelation plus zinc in decompensated cirrhosis, whereas standard management of symptomatic disease otherwise centers on chelation with penicillamine or trientine. PubMedPubMedTreatment patterns in a real-world cohort of patients with Wilson disease in the United States - PMC

Obtain a detailed neurologic examination in every patient with neurologic signs or symptoms and refer to a neurologist or movement-disorder specialist for a comprehensive assessment. Baseline neurologic characterization is necessary because neurologic worsening can occur after therapy initiation, particularly with penicillamine. PubMed+2PubMedComparative management practices of Wilson disease in Californian and Italian providers - PMCWolters KluwerWilson disease: Clinical manifestations,... : Clinical Liver DiseasePubMedTreatment patterns in a real-world cohort of patients with Wilson disease in the United States - PMC

In a patient with unexplained liver disease, neurologic disease, psychiatric manifestations, Coombs-negative hemolytic anemia, or a compatible family history, obtain serum ceruloplasmin and a 24-hour urine copper collection as initial copper studies. Ceruloplasmin below 10 mg/dL and urinary copper above 100 micrograms per 24 hours favor Wilson disease. Wiley+1WileyMinimal Criteria to Screen for Wilson Disease: A Delphi ...PubMedWilson Disease - StatPearls - NCBI Bookshelf

Interpret copper studies in clinical context. Urinary copper testing is specifically limited during acute hepatitis, and fulminant presentations may not permit timely acquisition of ceruloplasmin, 24-hour urine copper, or hepatic copper results. Do not use a delayed or discordant result in that setting to defer lifesaving liver-transplant evaluation. Wiley+2WileyIs it possible to diagnose fulminant Wilson's disease with ...PubMedClinical practice guidelines in Wilson disease - PMCPubMedWilson Disease - StatPearls - NCBI Bookshelf

Request slit-lamp examination for Kayser-Fleischer rings when Wilson disease is suspected, particularly in neurologic presentations. When clinical and biochemical testing is ambiguous, incorporate ATP7B molecular testing and other components of the Leipzig diagnostic index, which combines clinical, biochemical, and molecular findings; a Leipzig score of at least 4 is used as a diagnostic threshold in clinical trial confirmation criteria. PubMed+3PubMedWilson Disease - GeneReviews® - NCBI BookshelfPubMedWilson disease: a summary of the updated AASLD Practice GuidancePubMedWilson Disease - StatPearls - NCBI Bookshelfcdn clinicaltrialsPROTOCOL TITLE PAGE

Screen first-degree relatives with clinical and genetic testing. Family-directed testing enables diagnosis before irreversible hepatic or neurologic injury and supports initiation of lifelong treatment in affected relatives. PubMed+2PubMedClinical practice guidelines in Wilson disease - PMCPubMedWilson Disease - StatPearls - NCBI BookshelfPubMedPenicillamine - StatPearls - NCBI Bookshelf

Initiate lifelong medical therapy in newly diagnosed Wilson disease. Initial treatment aims to remove or detoxify accumulated tissue copper and typically uses a chelator; maintenance prevents reaccumulation with continued chelation at a reduced dose or zinc salts. Discontinuation can lead to neurologic or psychiatric symptoms or acute liver failure. Wolters Kluwer+1Wolters KluwerWilson disease: Clinical manifestations,... : Clinical Liver DiseasePubMedPenicillamine - StatPearls - NCBI Bookshelf

Use penicillamine or trientine as initial therapy for symptomatic patients. Penicillamine increases urinary copper excretion but has substantial long-term tolerability limitations, with approximately 30% of patients unable to tolerate it because of adverse effects; some patients with neurologic manifestations develop worsening that may be irreversible. Trientine is a reasonable primary alternative because it has a lower incidence of adverse effects, although neurologic deterioration has rarely been reported after initiation. Wolters Kluwer+2Wolters KluwerWilson disease: Clinical manifestations,... : Clinical Liver DiseaseWolters KluwerProspective Study to Assess Long‐Term Outcomes of... : JGH OpenPubMedTreatment patterns in a real-world cohort of patients with Wilson disease in the United States - PMC

For pediatric initial penicillamine treatment, the AASLD-referenced dose is 20 mg/kg/day. Do not extrapolate this pediatric dose to adults without product-specific prescribing information and specialist oversight. PubMedPubMedPenicillamine - StatPearls - NCBI Bookshelf

Use zinc as maintenance therapy after initial chelation in patients with Wilson disease; FDA labeling for zinc acetate specifies this indication. Zinc blocks dietary copper absorption and increases metallothionein. Zinc may also be selected as first-line therapy in presymptomatic patients without organ damage under AASLD and EASL approaches, while ESPGHAN favors zinc monotherapy in that setting. dailymed nlm nih+2dailymed nlm nihGALZIN® (Zinc Acetate) CapsulesWolters KluwerWilson disease: Clinical manifestations,... : Clinical Liver DiseasePubMedTreatment patterns in a real-world cohort of patients with Wilson disease in the United States - PMC

Avoid assuming that zinc is interchangeable with chelation in symptomatic hepatic disease. Long-term observational data found treatment discontinuation from failure, transplantation, or death in 18 of 88 zinc-treated patients and suggested chelators may better prevent hepatic deterioration; identify nonresponse early by clinical and urinary copper monitoring and assess adherence before declaring pharmacologic failure. Wolters KluwerWolters KluwerZinc Maintenance Therapy for Wilson Disease: A... : Hepatology Communications

At follow-up, assess hepatic status, neurologic and psychiatric manifestations, and adherence alongside copper indices and hematologic parameters. Routine monitoring should include biochemical testing and clinical evaluation; regular liver tests, copper indices, and hematologic parameters help detect adverse effects and treatment failure. Nature+1NatureClinical Management of Wilson's DiseasePubMedWilson Disease - GeneReviews® - NCBI Bookshelf

During chelation, measure 24-hour urinary copper excretion. Excretion is highest soon after therapy begins and may exceed 1,000 to 2,000 micrograms daily; during maintenance, approximately 200 to 500 micrograms daily is expected. In a patient previously excreting 200 to 500 micrograms daily, a value above 500 micrograms daily suggests either nonadherence to penicillamine or increased copper intake. PubMedPubMedPenicillamine - StatPearls - NCBI Bookshelf

For zinc acetate, monitor existing Wilson disease manifestations, 24-hour urinary copper, neuropsychiatric status including speech, liver tests including bilirubin and aminotransferases, and hematologic indices. Extended zinc exposure can cause copper deficiency with anemia, granulocytopenia, leukopenia, neutropenia, pancytopenia, thrombocytopenia, or myeloneuropathy. dailymed nlm nihdailymed nlm nihGALZIN® (Zinc Acetate) Capsules

When clinical deterioration or an unfavorable copper trend occurs, first verify medication access, dosing schedule, and adherence before changing agents. Zinc failure may reflect inadequate dose, intolerance, or nonadherence, but persistent hepatic deterioration warrants reassessment for chelation and transplant-center involvement when cirrhosis is decompensated. Wolters Kluwer+2Wolters KluwerZinc Maintenance Therapy for Wilson Disease: A... : Hepatology CommunicationsPubMedTreatment patterns in a real-world cohort of patients with Wilson disease in the United States - PMCPubMedClinical Review - Trientine Hydrochloride (MAR-Trientine) - NCBI Bookshelf

Test first-degree relatives using clinical and genetic evaluation, then initiate treatment in those diagnosed before organ damage develops. Guideline approaches differ in the exact screening modality, but AASLD and ESPGHAN include clinical and genetic testing for first-degree relatives. PubMed+1PubMedClinical practice guidelines in Wilson disease - PMCPubMedWilson Disease - StatPearls - NCBI Bookshelf

Build adherence assessment into every visit because multiple daily dosing, tolerability, and treatment burden are major limitations of lifelong therapy. For zinc-treated patients, adherence is especially important because efficacy depends on appropriate dosage, tolerability, and compliance; unexplained biochemical or clinical worsening should prompt a medication-use review before labeling treatment failure. Wolters Kluwer+1Wolters KluwerZinc Maintenance Therapy for Wilson Disease: A... : Hepatology CommunicationsPubMedWilson disease: a summary of the updated AASLD Practice Guidance